ATE488586T1 - In vitro peptid-expressionsbank - Google Patents

In vitro peptid-expressionsbank

Info

Publication number
ATE488586T1
ATE488586T1 AT03793896T AT03793896T ATE488586T1 AT E488586 T1 ATE488586 T1 AT E488586T1 AT 03793896 T AT03793896 T AT 03793896T AT 03793896 T AT03793896 T AT 03793896T AT E488586 T1 ATE488586 T1 AT E488586T1
Authority
AT
Austria
Prior art keywords
peptide expression
vitro peptide
library
expression bank
making
Prior art date
Application number
AT03793896T
Other languages
English (en)
Inventor
Duncan Mcgregor
Richard Odegrip
Kevin Fitzgerald
Rosemarie Hederer
Bill Eldridge
Chris Ullman
Philip Kuhlman
David Coomber
Original Assignee
Isogenica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0220759A external-priority patent/GB0220759D0/en
Priority claimed from GB0304521A external-priority patent/GB0304521D0/en
Priority claimed from GB0304657A external-priority patent/GB0304657D0/en
Application filed by Isogenica Ltd filed Critical Isogenica Ltd
Application granted granted Critical
Publication of ATE488586T1 publication Critical patent/ATE488586T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1075—Isolating an individual clone by screening libraries by coupling phenotype to genotype, not provided for in other groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT03793896T 2002-09-06 2003-09-05 In vitro peptid-expressionsbank ATE488586T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0220759A GB0220759D0 (en) 2002-09-06 2002-09-06 Display library
GB0304521A GB0304521D0 (en) 2003-02-27 2003-02-27 Display library
GB0304657A GB0304657D0 (en) 2003-02-28 2003-02-28 Display library
PCT/GB2003/003860 WO2004022746A1 (en) 2002-09-06 2003-09-05 In vitro peptide expression libraray

Publications (1)

Publication Number Publication Date
ATE488586T1 true ATE488586T1 (de) 2010-12-15

Family

ID=31982028

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03793896T ATE488586T1 (de) 2002-09-06 2003-09-05 In vitro peptid-expressionsbank

Country Status (14)

Country Link
US (2) US7842476B2 (de)
EP (2) EP1534830B1 (de)
JP (1) JP4664677B2 (de)
KR (1) KR101051245B1 (de)
CN (1) CN100351375C (de)
AT (1) ATE488586T1 (de)
AU (1) AU2003260786B2 (de)
CA (1) CA2497496C (de)
DE (1) DE60335000D1 (de)
DK (1) DK1534830T3 (de)
IL (1) IL166903A (de)
NO (1) NO332949B1 (de)
PT (1) PT1534830E (de)
WO (1) WO2004022746A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0418651D0 (en) 2004-08-20 2004-09-22 Medical Res Council Method
GB0505420D0 (en) * 2005-03-16 2005-04-20 Isogenica Ltd Stable ligand selection method
GB0515115D0 (en) * 2005-07-22 2005-08-31 Isogenica Ltd Peptide characterisation
GB0806562D0 (en) 2008-04-10 2008-05-14 Fermentas Uab Production of nucleic acid
KR20110036638A (ko) * 2008-07-25 2011-04-07 리차드 더블유. 와그너 단백질 스크리닝 방법
DK2356269T3 (en) 2008-10-31 2016-08-15 Janssen Biotech Inc FIBRONECTIN TYPE III DOMAIN-BASED SCAFFOLD COMPOSITIONS, PROCEDURES AND APPLICATIONS
US20120004185A1 (en) 2009-02-27 2012-01-05 Atyr Pharma, Inc. Polypeptide structural motifs associated with cell signaling activity
GB201000352D0 (en) 2010-01-11 2010-02-24 Isogenica Ltd Antimicrobial peptides
WO2011139714A2 (en) 2010-04-26 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
ES2638311T3 (es) 2010-04-27 2017-10-19 Atyr Pharma, Inc. Descubrimiento innovador de composiciones terapéuticas, diagnósticas y de anticuerpos relacionadas con fragmentos de proteína de treonil ARNt sintetasas
AU2011248614B2 (en) 2010-04-27 2017-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
US8993723B2 (en) 2010-04-28 2015-03-31 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases
US9068177B2 (en) 2010-04-29 2015-06-30 Atyr Pharma, Inc Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
CA2797393C (en) 2010-04-29 2020-03-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
JP6008838B2 (ja) 2010-04-29 2016-10-19 エータイアー ファーマ， インコーポレイテッド アスパラギニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
PT2571531T (pt) 2010-04-30 2016-08-31 Janssen Biotech Inc Composições do domínio da fibronectina estabilizadas, métodos e utilizações
EP2566496B1 (de) 2010-05-03 2018-02-28 aTyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von methionyl-trna-synthetasen
EP2566516B1 (de) 2010-05-03 2019-07-03 aTyr Pharma, Inc. Innovative entdeckung von therapeutischen und diagnostischen mitteln sowie antikörperzusammensetzungen im zusammenhang mit proteinfragmenten von seryl-trna-synthetasen
WO2011140132A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
JP5976638B2 (ja) 2010-05-03 2016-08-23 エータイアー ファーマ， インコーポレイテッド アルギニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
CN103096909A (zh) 2010-05-04 2013-05-08 Atyr医药公司 与谷氨酰-脯氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
AU2011248101B2 (en) 2010-05-04 2016-10-20 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex
US8945541B2 (en) 2010-05-14 2015-02-03 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases
WO2011146410A2 (en) 2010-05-17 2011-11-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases
US8962560B2 (en) 2010-06-01 2015-02-24 Atyr Pharma Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Lysyl-tRNA synthetases
US20130202576A1 (en) 2010-07-12 2013-08-08 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases
WO2012009289A2 (en) 2010-07-12 2012-01-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases
US8999321B2 (en) 2010-07-12 2015-04-07 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
AU2011289831C1 (en) 2010-07-12 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
GB201013284D0 (en) 2010-08-06 2010-09-22 Isogenica Ltd Scaffold peptides
WO2012027611A2 (en) 2010-08-25 2012-03-01 Atyr Pharma, Inc. INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-tRNA SYNTHETASES
US9399770B2 (en) 2010-10-06 2016-07-26 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tryptophanyl-tRNA synthetases
WO2012074029A1 (ja) 2010-12-01 2012-06-07 田辺三菱製薬株式会社 無細胞翻訳系でFabを提示しうるポリヌクレオチド構築物ならびにそれを用いたFabの製造方法およびスクリーニング方法
WO2013022982A2 (en) 2011-08-09 2013-02-14 Atyr Pharma, Inc. Pegylated tyrosyl-trna synthetase polypeptides
KR102142385B1 (ko) 2011-09-27 2020-08-10 얀센 바이오테크 인코포레이티드 대체 결합 표면을 가진 피브로넥틴 유형 iii 반복체 기반의 단백질 스캐폴드
US20130090265A1 (en) 2011-10-11 2013-04-11 Biolauncher Ltd. Systems and methods for generation of context-specific, molecular field-based amino acid substitution matrices
US20130090247A1 (en) 2011-10-11 2013-04-11 Biolauncher Ltd. Methods and systems for identification of binding pharmacophores
US20130090266A1 (en) 2011-10-11 2013-04-11 Biolauncher Ltd. Methods and systems for optimization of peptide screening
WO2013086216A1 (en) 2011-12-06 2013-06-13 Atyr Pharma, Inc. Improved aspartyl-trna synthetases
WO2013086228A1 (en) 2011-12-06 2013-06-13 Atyr Pharma, Inc. Pegylated aspartyl-trna synthetase polypeptides
JP6169608B2 (ja) 2011-12-29 2017-07-26 エータイアー ファーマ， インコーポレイテッド アスパルチルｔＲＮＡシンテターゼ−Ｆｃコンジュゲート
GB2500243A (en) * 2012-03-15 2013-09-18 Isogenica Ltd Identifying members of immobilised peptide libraries comprising protein-DNA complexes
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
EP2922872B1 (de) 2012-11-21 2018-10-10 Janssen Biotech, Inc. Bispezifische egfr/c-met-antikörper
AU2014233436B2 (en) 2013-03-15 2019-12-05 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates
KR102478402B1 (ko) 2013-10-14 2022-12-15 얀센 바이오테크 인코포레이티드 시스테인 조작된 피브로넥틴 iii형 도메인 결합 분자
EP3262185B1 (de) 2015-02-27 2020-08-26 The University of Hong Kong Dna-anzeige und verfahren dafür
KR102788389B1 (ko) 2015-04-06 2025-03-31 서브도메인, 엘엘씨 드 노보 결합 도메인 함유 폴리펩티드 및 그의 용도
JP7366518B2 (ja) 2015-05-06 2023-10-23 ヤンセン バイオテツク，インコーポレーテツド 前立腺特異的膜抗原結合フィブロネクチンｉｉｉ型ドメイン
US10925932B2 (en) * 2016-06-03 2021-02-23 Janssen Biotech, Inc. Serum albumin-binding fibronectin type III domains
WO2017223180A2 (en) 2016-06-21 2017-12-28 Janssen Biotech, Inc. Cysteine engineered fibronectin type iii domain binding molecules
CA3036972A1 (en) 2016-09-14 2018-03-22 Janssen Biotech, Inc. Chimeric antigen receptors comprising bcma-specific fibronectin type iii domains and uses thereof
EP3554535A4 (de) 2016-12-14 2020-10-21 Janssen Biotech, Inc. Pd-l1-bindende fibronectin-typ iii-domänen
US10611823B2 (en) 2016-12-14 2020-04-07 Hanssen Biotech, Inc CD137 binding fibronectin type III domains
KR102568559B1 (ko) 2016-12-14 2023-08-18 얀센 바이오테크 인코포레이티드 Cd8a-결합 섬유결합소 iii형 도메인
EP3600394A4 (de) 2017-03-22 2021-04-14 Research Corporation Technologies, Inc. Manipulierte stabile ch2-polypeptide
JP7679175B2 (ja) 2017-04-20 2025-05-19 エータイアー ファーマ， インコーポレイテッド 肺の炎症を治療するための組成物および方法
CA3074317C (en) 2017-08-25 2024-06-18 Janssen Biotech, Inc. Fc.gamma.rii binding fibronectin type iii domains, their conjugates and multispecific molecules comprising them
US12491255B2 (en) 2019-10-14 2025-12-09 Aro Biotherapeutics Company EPCAM binding fibronectin type III domains
WO2021076546A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Cd71 binding fibronectin type iii domains
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
WO2021127353A1 (en) 2019-12-18 2021-06-24 Aro Biotherapeutics Company Serum albumin-binding fibronectin type iii domains and uses thereof
US12239710B2 (en) 2021-04-14 2025-03-04 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
CA3214552A1 (en) 2021-04-14 2022-10-20 Russell C. Addis Cd71 binding fibronectin type iii domains

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU638762B2 (en) 1989-10-05 1993-07-08 Optein Inc Cell-free synthesis and isolation of novel genes and polypeptides
CA2112130C (en) * 1991-06-27 1996-08-06 Cynthia A. Edwards Screening assay for the detection of dna-binding molecules
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
ATE250668T1 (de) * 1997-05-28 2003-10-15 Discerna Ltd Ribosom-komplexe als selektionspartikel für die in vitro anzeige und evolution von proteinen
DK1019496T3 (da) 1997-07-07 2005-01-10 Medical Res Council In vitro-sorteringsmetode
GB9718455D0 (en) 1997-09-02 1997-11-05 Mcgregor Duncan P Chimeric binding peptide library screening method
GB9900298D0 (en) 1999-01-07 1999-02-24 Medical Res Council Optical sorting method
CA2367212A1 (en) 1999-04-01 2000-10-12 Innogenetics N.V. A polypeptide structure for use as a scaffold
EP1350846A4 (de) 2000-12-07 2005-01-26 Univ Keio C-terminales modifiziertes protein und verfahren zu seiner herstellung, bei der herstellung von c-terminalem modifiziertem protein zu verwendendes modifikationsmittel und translationsvorlage und verfahren zum nachweis von proteinwechselwirkung unter verwendung des c-terminalen modifizierten proteins
JP4963142B2 (ja) 2000-12-14 2012-06-27 学校法人慶應義塾 遺伝子型と表現型の対応付け分子とその構成要素、および対応付け分子の製造方法と利用方法
JP3706942B2 (ja) 2001-08-07 2005-10-19 学校法人慶應義塾 物質と蛋白質との間の相互作用の検出方法、物質と相互作用する蛋白質のスクリーニング方法、及び、物質とその物質と相互作用する蛋白質との複合体の形成方法
US20060156511A1 (en) * 2005-01-19 2006-07-20 Li Yuan J Caster

Also Published As

Publication number Publication date
AU2003260786B2 (en) 2008-03-13
US8679781B2 (en) 2014-03-25
US7842476B2 (en) 2010-11-30
EP2385118A1 (de) 2011-11-09
EP1534830B1 (de) 2010-11-17
EP1534830A1 (de) 2005-06-01
JP4664677B2 (ja) 2011-04-06
IL166903A (en) 2012-06-28
CA2497496C (en) 2012-05-15
US20120149591A1 (en) 2012-06-14
CN100351375C (zh) 2007-11-28
AU2003260786A1 (en) 2004-03-29
KR20050057216A (ko) 2005-06-16
CA2497496A1 (en) 2004-03-18
NO332949B1 (no) 2013-02-04
WO2004022746A1 (en) 2004-03-18
JP2005537795A (ja) 2005-12-15
DK1534830T3 (da) 2011-02-14
PT1534830E (pt) 2011-01-31
US20060035232A1 (en) 2006-02-16
HK1072957A1 (en) 2005-09-16
KR101051245B1 (ko) 2011-07-21
DE60335000D1 (de) 2010-12-30
NO20051685L (no) 2005-06-06
CN1681924A (zh) 2005-10-12

Similar Documents

Publication Publication Date Title
ATE488586T1 (de) In vitro peptid-expressionsbank
WO2002040683A3 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2002046407A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002046406A3 (en) Human transporter proteins, nucleic acid molecules encoding them,and uses thereof
WO2002022678A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2001081412A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding the same, and uses thereof
WO2002072831A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002077190A8 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
WO2002057310A3 (en) Human transporter proteins, nucleic acid molecules encoding them, and uses thereof
WO2002024910A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding them, and uses thereof
WO2003074675A3 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
WO2002046217A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002033086A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002020757A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002024748A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002081654A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2003070882A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and used thereof
WO2002053740A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002048364A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2001090360A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2001088136A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002048366A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002048365A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002066642A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002083731A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1534830

Country of ref document: EP